Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof

• US 10,087,175 B2
• Filed: 04/01/2015
• Issued: 10/02/2018
• Est. Priority Date: 04/01/2014
• Status: Active Grant

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Hawkins, William, Mach, Robert, Spitzer, Dirk, Vangveravong, Suwanna, Van Tine, Brian
• Primary Examiner(s): Bernhardt, Emily A
• Application Number:
  US15/301,188
• Publication Number:
  US 20170015660A1
• Time in Patent Office: 1,280 Days
• Field of Search: None
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 451/14 containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
• CPC Class Codes: C07D 471/08 Bridged systems

Abstract

Methods and compositions for treating cancers such as pancreatic cancer and synovial sarcoma are disclosed. Compounds comprising a sigma-2 receptor-binding moiety and a ferroptosis-inducing moiety are described. At least one described molecular species exhibits an IC₅₀ value below 5 μM against human pancreatic cancer cells in vitro. Administration of this species promoted shrinkage of pancreatic cancer tumors in a murine model system in vivo, and led to 100% survival of experimental animals over a time course in which control therapies provided only 30% or 40% survival. Methods of synthesis of molecular species are also disclosed.

Claims

1. A compound of structural Formula IV

2. A compound or a salt thereof in accordance with claim 1, wherein n=1 and R₂ is H.

3. A compound or a salt thereof in accordance with claim 1, wherein n=5 and R₂ is H.

4. A compound or a salt thereof in accordance with claim 1, wherein the salt is an oxalate or a hydrochloride salt.

6. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

7. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising the step of administering to the subject a therapeutically effective amount of a compound of claim 1, or a salt thereof.

8. The method according to claim 7, wherein the subject is a human.

9. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising administering the compound or salt thereof is the compound or salt thereof of claim 2.

10. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising administering the compound or salt thereof is the compound or salt thereof of claim 3.

11. A method of treating a pancreatic cancer or a synovial sarcoma in a subject in need thereof, comprising the sequential or co-administration of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and an additional anticancer drug.

12. The method according to claim 11, wherein the anticancer drug is chosen from an alkylating agent, anthracycline, antimetabolite agent, crosslinking agent, DNA replication inhibitor, intercalator, microtubule disruptor, PARP inhibitor, radiomimetic agent, radiosensitizer, strand break agent, and topoisomerase II inhibitor.

13. The method according to claim 11, wherein the anticancer drug is chosen from aminoglutethimide, amsacrine, anastrozole, asparaginase, barasertib, bcg, bicalutamide, bleomycin, buserelin, busulfan, campothecin, capecitabine, carboplatin, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, olaparib, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, perifosine, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, sorafenib, streptozocin, sunitinib, suramin, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.

14. The method of claim 11, wherein the method further comprises administering radiation therapy.

15. The method of claim 11, wherein the method further comprises administering surgery, thermoablation, focused ultrasound therapy, cryotherapy, or any combination thereof.

16. A compound or a salt thereof in accordance with claim 2, wherein the salt is an oxalate or a hydrochloride salt.

17. A compound or a salt thereof in accordance with claim 3, wherein the salt is an oxalate or a hydrochloride salt.

18. A pharmaceutical composition comprising the compound of claim 2 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

19. A pharmaceutical composition comprising the compound of claim 3 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

20. A pharmaceutical composition comprising the compound of claim 4 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

21. A pharmaceutical composition comprising the compound of claim 16 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

22. A pharmaceutical composition comprising the compound of claim 17 and one or more pharmaceutically acceptable excipients, adjuvants, or vehicles.

23. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 6 to a patient in need thereof.

24. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 18 to a patient in need thereof.

25. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 19 to a patient in need thereof.

26. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 20 to a patient in need thereof.

27. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 21 to a patient in need thereof.

28. A method for treating pancreatic cancer or synovial sarcoma, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 22 to a patient in need thereof.

5. A compound chosen from: